GSK1059615PI3K and mTOR inhibitor,potent and reversible CAS# 958852-01-2 |
- Lenalidomide hydrochloride
Catalog No.:BCC1697
CAS No.:1243329-97-6
- GSK J1
Catalog No.:BCC2231
CAS No.:1373422-53-7
- Necrostatin-1
Catalog No.:BCC2247
CAS No.:4311-88-0
- IOX2(Glycine)
Catalog No.:BCC2229
CAS No.:931398-72-0
Quality Control & MSDS
Number of papers citing our products
Chemical structure
3D structure
Cas No. | 958852-01-2 | SDF | Download SDF |
PubChem ID | 23582824 | Appearance | Powder |
Formula | C18H11N3O2S | M.Wt | 333.36 |
Type of Compound | N/A | Storage | Desiccate at -20°C |
Solubility | DMSO : 5 mg/mL (15.00 mM; Need ultrasonic) H2O : < 0.1 mg/mL (insoluble) | ||
Chemical Name | (5Z)-5-[(4-pyridin-4-ylquinolin-6-yl)methylidene]-1,3-thiazolidine-2,4-dione | ||
SMILES | C1=CC2=NC=CC(=C2C=C1C=C3C(=O)NC(=O)S3)C4=CC=NC=C4 | ||
Standard InChIKey | QDITZBLZQQZVEE-YBEGLDIGSA-N | ||
Standard InChI | InChI=1S/C18H11N3O2S/c22-17-16(24-18(23)21-17)10-11-1-2-15-14(9-11)13(5-8-20-15)12-3-6-19-7-4-12/h1-10H,(H,21,22,23)/b16-10- | ||
General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. |
Description | Potent inhibitor of PI 3-kinase α (PI3Kα) (IC50 = 2 nM). Inhibits proliferation in BT474 cells and attenuates MAPK signaling. |
GSK1059615 Dilution Calculator
GSK1059615 Molarity Calculator
1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
1 mM | 2.9998 mL | 14.9988 mL | 29.9976 mL | 59.9952 mL | 74.994 mL |
5 mM | 0.6 mL | 2.9998 mL | 5.9995 mL | 11.999 mL | 14.9988 mL |
10 mM | 0.3 mL | 1.4999 mL | 2.9998 mL | 5.9995 mL | 7.4994 mL |
50 mM | 0.06 mL | 0.3 mL | 0.6 mL | 1.1999 mL | 1.4999 mL |
100 mM | 0.03 mL | 0.15 mL | 0.3 mL | 0.6 mL | 0.7499 mL |
* Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. |
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
GSK1059615 is inhibitor of pan-PI3K with IC50 values of 0.4nM, 0.6nM, 5nM, 2nM and 12nM for PI3Kα, P13Kβ, P13Kγ, P13Kδ and mTOR, respectively [1].
GSK1059615 is a potent and reversible inhibitor of P13K. It also has inhibition efficacy to the oncogenic mutants of PI3Kα. The thiazolidinedione ring of GSK1059615 forms an interaction with the catalytic lysine (Lys833) within the ATP-binding pocket. In cellular assay, GSK1059615 is reported to induce G1 arrest and apoptosis in a variety of cell lines. Among these, the breast tumor cells display more sensitive. Moreover, GSK1059615 significantly suppresses tumor growth and increases plasma insulin levels in xenograft mice [1, 2].
References:
[1] Carnero A. Novel inhibitors of the PI3K family. 2009.
[2] Knight S D, Adams N D, Burgess J L, et al. Discovery of GSK2126458, a highly potent inhibitor of PI3K and the mammalian target of rapamycin. ACS Medicinal Chemistry Letters, 2010, 1(1): 39-43.
- SID 26681509
Catalog No.:BCC2362
CAS No.:958772-66-2
- (E)-1-(4-Hydroxyphenyl)dec-1-en-3-one
Catalog No.:BCN4031
CAS No.:958631-84-0
- Momordin IIa
Catalog No.:BCN3474
CAS No.:95851-50-6
- Momordin II
Catalog No.:BCN3473
CAS No.:95851-41-5
- Ipsapirone
Catalog No.:BCC7201
CAS No.:95847-70-4
- Hedyotisol B
Catalog No.:BCN4752
CAS No.:95839-45-5
- Piperlotine D
Catalog No.:BCN6494
CAS No.:958296-13-4
- AGN 196996
Catalog No.:BCC5417
CAS No.:958295-17-5
- CPI-613
Catalog No.:BCC2287
CAS No.:95809-78-2
- MPC-3100
Catalog No.:BCC2128
CAS No.:958025-66-6
- HIV-1 integrase inhibitor 2
Catalog No.:BCC1619
CAS No.:957890-42-5
- Fmoc-Phe(4-NH2)-OH
Catalog No.:BCC3154
CAS No.:95753-56-3
- 12-Hydroxy-8(17),13-labdadien-16,15-olide
Catalog No.:BCN1298
CAS No.:958885-86-4
- Sotalol hydrochloride
Catalog No.:BCC5165
CAS No.:959-24-0
- 2-Benzoylacetanilide
Catalog No.:BCC8560
CAS No.:959-66-0
- A922500
Catalog No.:BCC2333
CAS No.:959122-11-3
- PF 750
Catalog No.:BCC7641
CAS No.:959151-50-9
- 4-Hydroxyalternariol 9-methyl ether
Catalog No.:BCN7389
CAS No.:959417-17-5
- 5,7,4-Trihydroxy-3,6-dimethoxy-3-prenylflavone
Catalog No.:BCN1297
CAS No.:959421-20-6
- TC-E 5005
Catalog No.:BCC6227
CAS No.:959705-64-7
- Guggulsterone Z
Catalog No.:BCN3793
CAS No.:95975-55-6
- CH5138303
Catalog No.:BCC5364
CAS No.:959763-06-5
- Guajadial
Catalog No.:BCN4509
CAS No.:959860-49-2
- Aminothiazole
Catalog No.:BCC4623
CAS No.:96-50-4
Inhibition of gastric cancer cell growth by a PI3K-mTOR dual inhibitor GSK1059615.[Pubmed:30765226]
Biochem Biophys Res Commun. 2019 Mar 26;511(1):13-20.
Gastric cancer (GC) is a common malignancy. Developing novel and efficient anti-GC agents is urgent. GSK1059615 is a PI3K (phosphatidylinositol 3-kinase) and mTOR (mammalian target of rapamycin) dual inhibitor. It activity in human GC cells is tested here. In AGS cells and primary human GC cells, GSK1059615 potently inhibited cell growth, survival, proliferation and cell cycle progression. Further, significant apoptosis activation was detected in GSK1059615-treated GC cells. Contrarily in the primary human gastric epithelial cells, GSK1059615 failed to induce significant cytotoxicity and apoptosis. GSK1059615 blocked PI3K-AKT-mTOR cascade activation, inducing microRNA-9 downregulation but LMX1A (LIM homeobox transcription factor 1alpha) upregulation in GC cells. Significantly, GSK1059615 administration (i.p., daily, at 10 or 30mg/kg) in nude mice potently inhibited subcutaneous AGS xenograft growth. AKT-mTOR inhibition and LMX1A upregulation were detected in AGS xenograft tissues with GSK1059615 administration. Together, we conclude that GSK1059615 inhibits GC cell growth in vitro and in vivo.
GSK1059615 kills head and neck squamous cell carcinoma cells possibly via activating mitochondrial programmed necrosis pathway.[Pubmed:28881606]
Oncotarget. 2017 Feb 7;8(31):50814-50823.
This study tested the anti-head and neck squamous cell carcinoma (HNSCC) cell activity by GSK1059615, a novel PI3K and mTOR dual inhibitor. GSK1059615 inhibited survival and proliferation of established (SCC-9, SQ20B and A253 lines) and primary human HNSCC cells. GSK1059615 blocked PI3K-AKT-mTOR activation in HNSCC cells. Intriguingly, GSK1059615 treatment in HNSCC cells failed to provoke apoptosis, but induced programmed necrosis. The latter was tested by mitochondria depolarization, ANT-1-cyclophilin-D mitochondrial association and lactate dehydrogenase (LDH) release. Reversely, mPTP blockers (sanglifehrin A, cyclosporin A and bongkrekic acid) or cyclophilin-D shRNA dramatically alleviated GSK1059615-induced SCC-9 cell death. Further studies demonstrated that GSK1059615 i.p. injection suppressed SCC-9 tumor growth in nude mice, which was compromised with co-administration with cyclosporin A. Thus, targeting PI3K-AKT-mTOR pathway by GSK1059615 possibly provokes programmed necrosis pathway to kill HNSCC cells.
Gerosuppression by pan-mTOR inhibitors.[Pubmed:28077803]
Aging (Albany NY). 2016 Dec 30;8(12):3535-3551.
Rapamycin slows organismal aging and delays age-related diseases, extending lifespan in numerous species. In cells, rapamycin and other rapalogs such as everolimus suppress geroconversion from quiescence to senescence. Rapamycin inhibits some, but not all, activities of mTOR. Recently we and others demonstrated that pan-mTOR inhibitors, known also as dual mTORC1/C2 inhibitors, suppress senescent phenotype. As a continuation of these studies, here we investigated in detail a panel of pan-mTOR inhibitors, to determine their optimal gerosuppressive concentrations. During geroconversion, cells become hypertrophic and flat, accumulate lysosomes (SA-beta-Gal staining) and lipids (Oil Red staining) and lose their re-proliferative potential (RPP). We determined optimal gerosuppressive concentrations: Torin1 (30 nM), Torin 2 (30 nM), AZD8055 (100 nM), PP242 (300 nM), both KU-006379 and GSK1059615 (1000 nM). These agents decreased senescence-associated hypertrophy with IC50s: 20, 18, 15, 200 and 400 nM, respectively. Preservation of RPP by pan-mTOR inhibitors was associated with inhibition of the pS6K/pS6 axis. Inhibition of rapamycin-insensitive functions of mTOR further contributed to anti-hypertrophic and cytostatic effects. Torin 1 and PP242 were more "rapamycin-like" than Torin 2 and AZD8055. Pan-mTOR inhibitors were superior to rapamycin in suppressing hypertrophy, senescent morphology, Oil Red O staining and in increasing so-called "chronological life span (CLS)". We suggest that, at doses lower than anti-cancer concentrations, pan-mTOR inhibitors can be developed as anti-aging drugs.
Phosphatidylinositol-3-kinase as a therapeutic target in melanoma.[Pubmed:19383818]
Clin Cancer Res. 2009 May 1;15(9):3029-36.
PURPOSE: Phosphatidylinositol-3 kinases (PI3K) are critical for malignant cellular processes including growth, proliferation, and survival, and are targets of drugs in clinical development. We assessed expression of PI3K in melanomas and nevi, and studied associations between PI3K pathway members and in vitro response to a PI3K inhibitor, LY294002. EXPERIMENTAL DESIGN: Using Automated Quantitative Analysis, we quantified expression of p85 and p110alpha subunits in 540 nevi and 523 melanomas. We determined the IC(50) for LY294002 for 11 melanoma cell lines and, using reverse phase protein arrays, assessed the association between levels of PI3K pathway members and sensitivity to LY294002. RESULTS: p85 and p110alpha tend to be coexpressed (P < 0.0001); expression was higher in melanomas than nevi (P < 0.0001) for both subunits, and higher in metastatic than primary melanomas for p85 (P < 0.0001). Although phospho-Akt (pAkt) levels decreased in all cell lines treated with LY294002, sensitivity was variable. We found no association by t tests between baseline p85, p110alpha, and pAkt levels and sensitivity to LY294002, whereas pS6 Ser(235) and Ser(240) were lower in the more resistant cell lines (P = 0.01 and P = 0.004, respectively). CONCLUSIONS: Expression of p85 and p110alpha subunits is up-regulated in melanoma, indicating that PI3K is a good drug target. Pretreatment pS6 levels correlated with sensitivity to the PI3K inhibitor, LY294002, whereas PI3K and pAkt did not, suggesting that full activation of the PI3K pathway is needed for sensitivity to PI3K inhibition. pS6 should be evaluated as a predictor of response in melanoma patients treated with PI3K inhibitors, as these drugs enter clinical trials.